Should You Ignore Rocket Lab Stock? Why SpaceX May Be the Better Space Stock Today.

The market is treating this less like a launch-services story and more like a credibility trade: the public market is discounting any "next SpaceX" narrative until Rocket Lab proves it can close the product gap without repeated schedule slippage. That matters because in this category, valuation is driven less by revenue growth than by the probability-weighted path to operating leverage; every quarter of delay keeps RKLB trapped in a lower multiple regime while the category leader compounds a much wider moat.

The Iridium deal is the key second-order lever. It can improve near-term cash generation optics, but it also raises integration risk and increases the odds that future upside gets diluted by financing or stock-based consideration; if the market starts to price in deal complexity rather than synergies, the transaction becomes a valuation overhang instead of a catalyst. Meanwhile, SpaceX's multi-product platform reduces the addressable upside for smaller launch pure-plays and pressures satellite-comms incumbents by making vertical integration a defensive necessity.

Near term, the cleanest catalyst is not another contract award but any sign that Neutron slips again or that management must guide around launch timing to defend the profitability bridge. Over 6-18 months, the thesis flips only if RKLB demonstrates on-time Neutron progress and converts the Iridium asset into verifiable FCF without incremental dilution. The contrarian view is that the selloff may be a bit too reflexive if the market is underestimating how quickly a profitable, cash-generative RKLB could rerate once execution risk starts to fade; the key is that this rerating is binary and needs hard proof, not narrative.